Avanzanite licenses Zemcelpro stem cell therapy commercialisation rights across 32 European countries

Avanzanite has secured exclusive European commercialisation rights to Cordex Biologics' conditionally authorised cord-blood stem cell therapy Zemcelpro, covering 32 countries under new licensing and supply agreements.
Avanzanite Bioscience and Cordex Biologics announced exclusive licensing and supply agreements on 9 November 2026 covering Zemcelpro (dorocubicel) across the European Economic Area, United Kingdom and Switzerland, with Avanzanite assuming commercial responsibilities and the existing EU marketing authorisation following regulatory transfer.
The allogeneic cord-blood-derived therapy received European Commission conditional marketing authorisation on 25 August 2025 for specified adults with haematological malignancies requiring transplantation when suitable donor cells are unavailable, while Cordex retains manufacturing and global development responsibilities and the new agreements include undisclosed development fees, commercial milestones and royalties.
Field | Content |
Article Type | Deals |
Licensee | Avanzanite Bioscience |
Licensor | Cordex Biologics |
Deal Type | Exclusive commercialisation licensing and supply agreements |
Announcement Date | 9 November 2026 |
Agreement Status | Announced |
Licensed Product | Zemcelpro |
Active Ingredient | Dorocubicel |
Technology Designation | UM171 cell therapy |
Therapy Type | Allogeneic cord-blood-derived stem cell therapy |
Therapeutic Area | Haematology and oncology |
Target Patient Population | Eligible adults with haematological malignancies requiring stem cell transplantation when suitable donor cells are unavailable |
Treatment Context | Haematopoietic stem cell transplantation |
Licensed Territory | 32 European countries |
Territory Coverage | European Economic Area, United Kingdom and Switzerland |
Commercial Rights | Exclusive commercialisation rights within the licensed territory |
Licensee Responsibilities | Commercial operations and regional market access |
Marketing Authorisation Transfer | Avanzanite to assume the existing EU marketing authorisation following regulatory transfer |
Licensor Responsibilities | Manufacturing and global development |
Supply Arrangement | Commercial supply agreement included |
European Regulatory Authority | European Commission |
Existing EU Approval Type | Conditional marketing authorisation |
Existing EU Authorisation Date | 25 August 2025 |
UK Regulatory Status | Authorisation remains prospective as described in the supplied announcement |
Swiss Regulatory Status | Authorisation remains prospective as described in the supplied announcement |
Development Programme | Planned Phase III study |
Licensee Development Role | Support for the planned Phase III study |
Financial Structure | Development fees, commercial milestones and royalties |
Upfront Payment | Not disclosed |
Milestone Amounts | Not disclosed |
Royalty Rates | Not disclosed |
Total Deal Value | Not disclosed |
New European Commission Approval | No; the EU conditional authorisation predates the licensing announcement |
What Happened | Avanzanite obtained exclusive commercialisation rights to Zemcelpro across 32 European countries through licensing and supply agreements with Cordex. |
Why It Matters | The transaction establishes a dedicated European commercialisation arrangement for a specialised stem cell therapy addressing transplantation needs in haematological malignancies. |
Strategic Significance | Separates regional commercial execution from Cordex's retained manufacturing and global development responsibilities. |
Regulatory Clarification | Commercial rights covering the United Kingdom and Switzerland do not establish that Zemcelpro is authorised in those jurisdictions. |
Key Takeaway | Avanzanite will lead European commercialisation of Zemcelpro under undisclosed financial terms, subject to applicable regulatory and market-access requirements. |
What to Watch | Marketing authorisation transfer, country-level reimbursement, UK and Swiss regulatory progress, commercial launches and Phase III development. |
Primary Source | Avanzanite and Cordex licensing announcement |
Primary Source URL | https://www.prnewswire.com/news-releases/zemcelpro-um171-cell-therapy-licensing-and-supply-agreements-announced-for-europe-302933369.html |
Relevant Date | 9 November 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com

コメント